InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Two Awards in NIH’s AI PREPARE Challenge
October 3, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has won two awards in the Pioneering Research for Early Prediction of Alzheimer’s and Related Dementias EUREKA (“PREPARE”) Challenge; the awards were regarding IGC’s entry of the Mexican Health and Aging Study (“MHAS”) database. According to the announcement, the challenge, which is sponsored by the National Institute […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1’s Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer’s
September 18, 2024
IGC Pharma (NYSE American: IGC), an AI-powered, clinical-stage biotechnology company, today announced data that supports the therapeutic potential of IGC-AD1 as a disease modifying treatment for Alzheimer’s. According to the announcement, findings from studies have shown that IGC-AD1 has a significant, promising impact on tau pathology, as it effectively degrades the process strongly associated with […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
September 4, 2024
IGC Pharma (NYSE American: IGC), an AI-powered, clinical-stage biotechnology company, is announcing the advancement of its proprietary formulation, IGC-AD1, an orally administered medication with a strong safety profile, toward clinical trials as a potential anti-amyloid disease-modifying treatment for Alzheimer’s disease. According to the announcement, IGC Pharma is positioned to make a significant contribution with IGC-AD1 […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
August 27, 2024
IGC Pharma (NYSE American: IGC), an AI-powered, clinical stage biotechnology company, today announced results from its 2024 Annual Meeting of Stockholders held on August 23, 2024. According to the announcement, all proposals, as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 8, 2024, were passed by the requisite […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
August 22, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on its preclinical research that demonstrates the therapeutic potential of IGC-1C, a novel small-molecule modulator. According to the announcement, IGC-1C targets tau protein and GLP-1 receptors, offering a multipathway approach to neurodegenerative and metabolic disease treatment. A cyclic dipeptide-based, small-molecule modulator, IGC-1C is a pioneering […]
InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
August 20, 2024
IGC Pharma (NYSE American: IGC), an AI-powered, clinical stage biotechnology company, today announced the discovery of its proprietary molecule, IGC-1A, as a potential GLP-1 agonist. This revelation resulted from the company’s state-of-the-art Artificial Intelligence (“AI”) modeling. According to the announcement, the discovery highlights the versatility of IGC Pharma’s drug platforms. It also presents a significant […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
August 9, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the results for its first fiscal quarter of 2025, the period ended on June 30, 2024. According to the report, highlights for the company included the company’s collaboration with Pablo Arbelaez, a renowned AI expert and researcher, in the development of the phase 2 […]
InvestorNewsBreaks – PayPal Holdings Inc. (NASDAQ: PYPL) Launches Fastlane to Enhance E-Commerce Checkout Experience
August 8, 2024
PayPal Holdings (NASDAQ: PYPL) is making significant strides in the e-commerce sector with the launch of Fastlane, a service aimed at enhancing the online shopping experience. As a leading entity in digital payments, PayPal’s introduction of Fastlane underscores its commitment to streamlining the checkout process for businesses and consumers alike. This move comes at a crucial […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
July 18, 2024
IGC Pharma (NYSE American: IGC) today announced that Alliance Global Partners (“AGP”) has issued an analyst coverage research report on the company’s common stock. AGP issued a “Buy” recommendation and a $3.50 price target. “All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC […]
InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings
July 9, 2024
IGC Pharma (NYSE American: IGC) today announced preclinical data demonstrating TGR-63’s potential as an effective treatment for Alzheimer’s disease. Analysis of the partition coefficient and mass spectrometry of brain tissue in Alzheimer’s murine models indicates that TGR-63 has the potential to cross the blood-brain barrier in humans. The findings build on earlier results demonstrating TGR-63’s […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies
June 26, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on preclinical results in an Alzheimer’s mouse model. According to the announcement, the model demonstrates the potential of IGC Pharma’s therapeutic candidate, TGR-63, to combat Alzheimer’s disease. Specifically, the students show a “significant reduction” in amyloid plaque, totaling 78% in the cortex and 85% in […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year
June 25, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on its financial results for the fiscal year ended March 31, 2024. Highlights of the report show the company gathered positive interim results from its ongoing phase 2 trial for IGC-AD1; updated information TGR-63, IGC’s drug candidate, which targets amyloid-beta plaque; received three patents; signed […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event
June 18, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, will be featured during an upcoming fireside chat hosted by Ascendiant Capital Markets. According to the announcement, IGC Pharma CEO Ram Mukunda and CCO Claudia Grimaldi will be presenting during the event, which is slated to begin at 12 p.m. ET on June 27, 2024. During the […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Publication of Key Study in European Journal
June 10, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has published a significant research study. The company announced that the study, titled “A study on CYP2C9 polymorphism in Puerto Rican Alzheimer’s Patients and its role in the Pharmacokinetics of ∆-9-tetrahydrocannabinol,” was published in the “European Society of Medicine” journal. According to the announcement, the study investigates […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Initiates Patient Enrollment in Phase 2 Trial Investigating IGC-AD1
May 28, 2024
IGC Pharma (NYSE American: IGC) today announced patient enrollment at Neurostudies Inc. in Port Charlotte, Florida, for its Phase 2 clinical trial investigating IGC-AD1 as a potential treatment for agitation in Alzheimer’s disease. According to the announcement, IGC Pharma is currently conducting a Phase 2 trial with IGC-AD1, a partial CB1r agonist with anti-neuroinflammatory properties […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Management Hosting Meetings at Upcoming BIO International Convention 2024
May 22, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, will be participating at next month’s BIO International Convention. The four-day event is scheduled for June 3–6, 2024, in San Diego, California. According to the company, members of its management team will be at the conference and will be hosting meetings with pharmaceutical executives. The purpose of […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Shares Positive Interim Results on IGC-AD1 for Agitation in Alzheimer’s
April 16, 2024
IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced that interim data from its phase 2 trial demonstrates a clinically significant reduction, approaching statistical significance, in agitation in Alzheimer’s at week two compared to placebo. IGC-AD1 targets neuroinflammation and CB1 receptor dysfunction, and the investigational drug […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Adds AI Expert to Support Development of Phase 2 Clinical Trial
April 9, 2024
IGC Pharma (NYSE American: IGC), a company focused on developing innovative solutions to address Alzheimer’s disease, has announced the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AI”) and one of the world’s top researchers. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC Pharma’s lead therapeutic candidate […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company
March 27, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management company. According to the announcement, IGC Pharma entered into a share purchase agreement (“SPA”) with Bradbury comprised of IGC issuing 8,823,529 shares of unregistered common stock […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation
March 21, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting on the interim analysis of its ongoing phase 2 trial. The trial is focused on evaluating the company’s proprietary IGC-AD1 as a treatment for agitation in dementia from Alzheimer’s Disease (“AAD”). According to the announcement, the interim data indicates that the study demonstrates clinical and […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024
March 20, 2024
IGC Pharma (NYSE American: IGC), a company focused on Alzheimer’s disease and developing innovative solutions to address this devastating illness, has announced that its CEO Ram Mukunda and Vice President Claudia Grimaldi will participate in a fireside chat at the Benzinga Virtual Healthcare Summit 2024. The event is slated to take place on March 20, […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors
March 13, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has appointed a new independent director to its board of directors. The company announced that healthcare veteran Terry Lierman has accepted the position. Lierman brings a rich background in healthcare to this new opportunity. He currently serves as cochair of the board of advisors at the Institute […]
HealthLynked Welcomes David Rosal as New Chief Financial Officer
March 13, 2024
NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) — via IBN — HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare network and services, is delighted to announce the appointment of David Rosal as its new Chief Financial Officer (CFO), effective March 18, 2024. With a distinguished career that spans over two decades, Rosal brings a […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment
February 28, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, reported on the results of preclinical studies evaluating its drug candidate TGR-63 as a treatment for Alzheimer’s disease. According to the report, the data showed enhanced memory function, including memory acquisition, consolidation and retrieval, in an Alzheimer’s mouse model. The preclinical studies included the use of two […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report
February 23, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is featured in a recent analyst coverage research report issued by Ascendiant Capital Markets LLC. The report included a “buy” recommendation with a $3 price target. The company noted that all reports prepared by analysts that spotlight IGC Pharma reflect the views of those analysts and are […]
Correlate Energy Corp. (CIPI) Anticipates Impressive Performance in 2024 Given Overall Global Shift to Renewable Energy Sources
February 22, 2024
As more people come to terms with the reality of climate change and the risks that come with it, there has been a massive shift to renewables across various social and economic sectors, at an increasing rate. This has presented new opportunities for companies such as Correlate Energy (OTCQB: CIPI), a publicly traded company capitalizing […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q3 2024 Financial Results, Reports Corporate Achievements
February 20, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting financial results and business updates for the third fiscal quarter of 2024, the period ended Dec. 31, 2023. Highlights of the report include the company receiving a patent from the European Patent Office covering a method for treating pain in humans and a patent from […]
Nextech3D.ai Featured in Syndicated Broadcast Highlighting Launch of Next Era of GPT AI 3D Solutions
February 20, 2024
LOS ANGELES, Feb. 20, 2024 (GLOBE NEWSWIRE) — via IBN — Nextech3D.ai (CSE: NTAR) (OTCQX: NEXCF) (FSE: 1SS), a Generative AI-Powered 3D model supplier for Amazon, P&G, Kohls, Miele and others including major e-commerce platform integrations with Shopify, BigCommerce and WooCommerce, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model
February 1, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting additional positive results from preclinical studies investigating its newly announced therapeutic candidate, TGR-63, a potential treatment for Alzheimer’s disease. The company had already shared study results indicating that TGR-63 shows potential to alleviate plaque burden in Alzheimer’s cell lines and animal models. New results exhibit […]
InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s
January 23, 2024
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is sharing details regarding its drug candidate TGR-63, which targets amyloid-beta plaque and has potential to improve Alzheimer’s disease treatment in a significant manner. According to the announcement, preclinical trial data shows TGRr-63 reduces plaque in Alzheimer’s. The company observed that “a key pathological marker of Alzheimer’s […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial
January 17, 2024
IGC Pharma (NYSE American: IGC) today announced that ClinCloud, a clinical research facility in Florida, has dosed its first patient as part of IGC’s ongoing phase 2b trial. The company is currently conducting the trial at twelve sites in the U.S. and Canada with IGC-AD1, a combination medicine with a CB1 receptor partial agonist with […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s
December 19, 2023
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a patent from Divisional Direction of Patents, Mexico. The agency issued a Granting Office Action (“GOA”) for IGC Pharma’s treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” According to the announcement, the company believes that the success of the patent in […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Biotech Showcase and BioPartnering @ JPM
December 13, 2023
IGC Pharma (NYSE American: IGC) has announced that its management team will participate in Biotech Showcase and BIO Partnering @ JPM, held in-person and scheduled alongside the J.P. Morgan 41st Annual Healthcare Conference 2024. The presentation at Biotech Showcase is slated to begin at 2 p.m. PT on Jan. 8, 2024, while the BIO Partnering […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Partners with Prominent Center to Integrate AI into Clinical Trials
December 6, 2023
IGC Pharma (NYSE American: IGC) is collaborating with the Los Andes University Center for Research and Training in Artificial Intelligence (“CINFONIA”) in a partnership designed to leverage generative artificial intelligence (“AI”) to analyze variations in disease signatures among patients. The collaboration will provide key data to help identify individuals more likely to respond to treatment. IGC is […]
InvestorNewsBreaks — Cool Amps Corp.’s CEO and Director Help Show That the Path to a Climate-Friendlier Future ‘Goes Through Chapel Street’
December 4, 2023
Cool Amps was featured in a recent article published by New Haven Independent. The piece covers the recent Tech Hub Grand Opening, discussing Cool Amps’ Lonnie Garris III and Nick Anderson’s attendance at the event in New Haven, Connecticut, celebrating “less carbon, more innovation,” where they showcased their company’s “laminar flow extraction module” prototype. “Retired […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Enters Strategic Collaboration to Advance AI Initiatives
November 21, 2023
IGC Pharma (NYSE American: IGC) has announced its entry into a master cooperation agreement with the University of Los Andes for the development and adoption of generative AI solutions into the company’s drug identification, development and clinical trial processes. IGC Pharma will be focused on advancing various AI initiatives including streamlining clinical trial efficiency, enhancing […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q2 2024 Financial, Corporate Report
November 13, 2023
IGC Pharma (NYSE American: IGC) is reporting financial and business results for second quarter 2023, the period ending Sept. 30, 2022. Highlights of the report include revenue in second quarter FY2024 increasing 44%, totaling an estimated $291,000 compared to the same quarter in FY2023, which was reported at approximately $202,000, with revenue in the first six months […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Cannabinoid-Based Topical Pain-Relief Treatment Receives European Patent
October 20, 2023
IGC Pharma (NYSE American: IGC), a visionary clinical-stage pharmaceutical company, has achieved a significant milestone; the company has received notice from the European Patent Office that the patent for its proprietary “Cannabinoid Composition and Method for Treating Pain” has been granted. According to the announcement, the patent covers IGC Pharma’s pioneering method for treating pain […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Results of Annual Meeting
August 21, 2023
IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive Proxy Statement on Schedule 14A filed with the SEC on July 26, 2023, were passed by the requisite vote of the stockholders. Only […]
InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report
August 14, 2023
IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps (dysmenorrhea), premenstrual syndrome (“PMS”) and chronic pain, is reporting on its financial and business results for the first quarter of the 2024 fiscal year, the period ended June 30, […]